The purpose of this study was to compare efÞ cacy and safety of ciclesonide (CIC) with budesonide (BUD) in the treatment of bronchial asthma.
Introduction
Bronchial asthma is one of the most abundant chronic inß ammatory disease of the airways, which is characterized by periodically recurrent attacks of breathlessness and wheezing. These symptoms vary in frequency and severity between individuals depending on stage of progression. Untreated asthma leads to an irreversible remodeling of the airways, which results in an airß ow limitation.
The main aim of the asthma therapy is to control the disease preventing exacerbations, maintaining proper airß ow and reducing the need of rescue therapies. The most effective and relatively safe drugs that are abundantly used in asthma controlling are inhaled corticosteroids. These drugs show anti-inß ammatory, anti-allergic and immunosuppressive activity. Long-term administration of corticosteroids results in a gradual reduction in bronchial hyperactivity.
Ciclesonide and budesonide are two of four inhaled corticosteroids available in Europe for asthma control.
Conclusions
Ciclesonide provides an improvement in spirometric parameters and reduction of asthma symptom-free days as compared to budesonide in 1:1 dose ratio, while no differences were noticed between CIC and BUD in 1:2 dose ratio. Cicleconide, as compared to budesonide in 1:1 daily dose ratio, provides concomitant risk reduction of upper respiratory tract infections.
Characteristics of clinical trials
The search in medical databases resulted in total number of 1278 identiÞ ed publications (including repeated titles). 155 positions were qualiÞ ed for full text analysis. Finally 7 trials met predeÞ ned inclusion criteria and were suitable for further analysis:
7 RCTs comparing CIC with BUD in patients with mild to moderate bronchial asthma
All studies had apparel design. Methodological credibility of the trials included in the analysis was medium in most cases.
• All patients in included studies were diagnosed with asthma. The severity of disease was not speciÞ ed in all studies included except for one trial in which recruited patient suffered from mild to moderate asthma. Ciclesonide was administered to patients in daily dose ranging from 200 mg up to 400 mg and the respective daily dose of budesonide was in the range of 400 to 800. Comparisons of both interventions in 1:1 and 1:2 dose ratios were assessed in 3 and 4 trials, respectively. Duration of treatment was equal in the studies and lasted 12 weeks. All of included trials were of moderate and high quality (respectively: 3 and 4 points according to Jadad scale).
Results

Effi cacy
CIC as compared with BUD in 1:1 dose ratio was associated with signiÞ cant improvement in forced vital capacity (FVC) and peak expiratory ß ow (PEF) by spirometry (WMD=0.09 [0.03; 0.14] and WMD=19.00 [2.37; 35.63] , respectively) as well as reduction in proportion of symptom-free days (p=0.018). Equivocal results were obtained for comparison of CIC with BUD in 1:1 dose ratio with respect to frequency of rescue medication use. While one of included studies showed signiÞ cant difference in favor of CIC (p=0.026), the other revealed similar results for both treatment groups. EfÞ cacy analysis of both therapeutic options in 1:2 dose ratio showed no signiÞ cant difference between groups in asthma exacerbation, days free from symptoms of asthma and spirometric measurements (Table 3 & Table 4 ).
Safety
CIC-treated patients experienced less upper respiratory tract infections (URTI) than those treated with BUD in 1:1 dose ratio, however the difference was on the border of statistical signiÞ cance (RR = 0.65 [0.43; 0.99], NNT not signiÞ cant). There were no statistically signiÞ cant differences between CIC and BUD in either dose ratio with respect to risk of total and treatment-related adverse events, serious and severe adverse events. No signiÞ cant difference was found as regard withdrawal from study due to adverse event and lack of efÞ cacy. In both treatment groups there were similar frequencies of pharyngitis, rhinitis, pharyngo-laryngeal pain, and dysphonia. (Table 5 )
Limitations
Limitations of the analysis were related to different approach to assessing and reporting of drug efÞ cacy between included trials what precluded metaanalyses. However, the conclusion was based on best available evidences, which took into account all studies showing different results.
Methods
Comparison of efÞ cacy and safety of analyzed drugs was based on randomized controlled trials ( 
